Trial · NCT05378971
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
NCT05378971, Not applicable, Unknown, LanZhou University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma. Trials, record NCT05378971. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05378971
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
- NCT number
- NCT05378971
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 15 participants, estimated
- Lead sponsor
- LanZhou University
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide
- First posted
- 2022-05-18
- Last updated
- 2023-10-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 2-year progression-free survival(2y-PFS) | up to 24 months. | 2y-PFS was defined as the proportion of patients who reached at least 2 years from the first day of treatment to the time of disease progression or death. |
| Secondary | 2-year overall survival(2y-OS) | up to 24 months. | 2y-OS was defined as the proportion of patients with a time from the first day of treatment to death of at least 2 years. |
| Secondary | Complete remission(CR) | up to 24 months. | It includes strict complete remission (sCR), CR: negative serum and urine immunofixation electrophoresis and bone marrow plasma cells \<5%; sCR: normal serum free light chain ratio and absence of clonal plasma cells in bone marrow confirmed by immunohistochemistry on the basis of meeting CR criteria; |
| Secondary | very good partial remission(VGPR) | up to 24 months. | VGPR: undetectable M protein by serum protein electrophoresis but still positive by serum and and urine immunofixation electrophoresis, or ≥90% reduction in M protein and urine M protein \<100 mg/24h. |
| Secondary | negative rate of minimal residual disease | up to 24 months. | Flow cytometry was used to detect cells with abnormal immunophenotype, and residual tumor cells \<10-4 were considered negative. |
| Secondary | adverse events | Adverse event reports are collected once a month during treatment, up to 24 months. | number of participants with treatment-related adverse events as assessed by CTCAE 5.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05378971
GET https://conductscience.org/api/trials/v1/NCT05378971/registered